Rheumatology International

, Volume 30, Issue 12, pp 1605–1609 | Cite as

RETRACTED ARTICLE: Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic

  • Siavash Nasiri
  • Mansoor KarimifarEmail author
  • Zahra Sayed Bonakdar
  • Mansour Salesi
Original Article


This study aimed to determine the correlation between of ESR, C3, C4, anti-DNA, and lupus activity and also the construct and criterion validity of the British Isles Lupus Assessment Group (BILAG) index for assessing disease activity in systemic lupus erythematosus (SLE). Patients with SLE were recruited into a cross-sectional study. Data were analyzed for estimating of SLE disease activity [scores on the BILAG index and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)]. Overall BILAG scores were determined by the highest score achieved in any of the individual systems in the respective index. Erythrocyte sedimentation rates (ESRs), C3 levels, C4 levels, anti-double-stranded DNA (anti-dsDNA) levels, and SLEDAI-2K scores were used in the analysis of construct validity. Statistical analyses were performed using ordinal logistic regression for construct validity. Of the 100 patients with SLE, 90% were women. Their mean ± SD age was 31.1 ± 9.8 years. Increasing overall scores on the BILAG index were associated with increasing ESRs, decreasing C3 levels, decreasing C4 levels, elevated anti-dsDNA levels, and increasing SLEDAI-2K scores (all P < 0.01). These findings show that the ESR, C3, C4, and anti-DNA should be used in the evaluation and management of patients with SLE. Also the results show that the BILAG index has construct validity.


Systemic lupus erythematosus ESR C3 C4 Anti-dsDNA BILAG index SLEDAI-2K 


  1. 1.
    Liang MH, Socher SA, Roberts WN, Esdaile JM (1988) Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817–825CrossRefPubMedGoogle Scholar
  2. 2.
    Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN et al (2005) BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:902–906CrossRefGoogle Scholar
  3. 3.
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458PubMedGoogle Scholar
  4. 4.
    Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS et al (2006) Revised British Isles Lupus Assessment Group 2004 Index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 54:3300–3305CrossRefPubMedGoogle Scholar
  5. 5.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  6. 6.
    Hochberg MC (1997) For the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
  7. 7.
    Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288–291PubMedGoogle Scholar
  8. 8.
    Williams RL (2000) A note on robust variance estimation for clustercorrelated data. Biometrics 56:645–646CrossRefPubMedGoogle Scholar
  9. 9.
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995–1002CrossRefPubMedGoogle Scholar
  10. 10.
    Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S et al (1993) HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 32:870–875CrossRefPubMedGoogle Scholar
  11. 11.
    Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC et al (1999) The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167:257–274CrossRefPubMedGoogle Scholar
  12. 12.
    Schotte H, Willeke P, Tidow N, Domschke W, Assmann G, Gaubitz M et al (2005) Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol 34:114–121CrossRefPubMedGoogle Scholar
  13. 13.
    Hartung K, Ehrfeld H, Lakomek HJ, Coldewey R, Lang B, Krapf F, SLE Study Group et al (1992) The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. Rheumatol Int 11:243–249CrossRefPubMedGoogle Scholar
  14. 14.
    Provost TT, Talal N, Bias W, Harley JB, Reichlin M, Alexander EL (1988) Ro(SS-A) positive Sjögren’s/lupus erythematosus (SC/LE) overlap patients are associated with the HLA-DR3 and/or DRw6 phenotypes. J Invest Dermatol 914:369–371CrossRefGoogle Scholar
  15. 15.
    Batchelor JR, Fielder AH, Walport MJ, David J, Lord DK, Davey N et al (1987) Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol 70:364–371PubMedPubMedCentralGoogle Scholar
  16. 16.
    Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMedGoogle Scholar
  17. 17.
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19:608–611PubMedGoogle Scholar
  18. 18.
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol 21:1468–1471PubMedGoogle Scholar
  19. 19.
    Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA et al (2004) Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 31:2390–2394PubMedGoogle Scholar
  20. 20.
    Davas EM, Tsirogianni A, Karamitsos D, Economoida I, Dantis PC (1999) Serum IL-6, TNF α, P55sr TNFα, P75sr TNFα, sr IL-2α level and disease activity in SLE. Clin Rheumatol 18:17–22CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Siavash Nasiri
    • 1
  • Mansoor Karimifar
    • 1
    Email author
  • Zahra Sayed Bonakdar
    • 1
  • Mansour Salesi
    • 1
  1. 1.Department of RheumatologyIsfahan University for Medical Sciences, Alzahra HospitalIsfahanIran

Personalised recommendations